HCPCS code J8650 – Nabilone, oral, 1 mg

Key takeaways

HCPCS Code J8650 described nabilone, oral, 1 mg (Cesamet), a Schedule II synthetic cannabinoid approved for chemotherapy-induced nausea and vomiting.

J8650 was deleted from HCPCS Level II effective January 2026, and claims submitted with it after that date deny automatically.

Billing teams should confirm the replacement code against the CMS HCPCS annual update crosswalk file and correct every charge master entry.

Practice management software like Pabau supports HCPCS code updates, clean claim submission, and denial tracking for oral oncology billing.

HCPCS Code J8650: definition and code description

HCPCS Code J8650 is the HCPCS Level II billing code for nabilone, oral, 1 mg. It sits in the J8500-J8999 range that CMS maintains for oral anticancer and antiemetic drugs. One unit equaled 1 mg, so billing teams reported units equal to the total milligrams dispensed or administered in the billing period.

The J8xxx range follows Medicare billing rules that differ from the injectable J-codes in the J0100-J8499 range. That distinction matters once you start looking for the code or the NOC entry that carries nabilone after the January 2026 deletion.

CMS maintains HCPCS Level II, which covers drugs, supplies, and services that CPT does not. CPT codes are Level I and belong to the AMA. For oral anticancer and antiemetic agents, the J8xxx codes are the billing vehicle whenever Medicare Part B applies.

J8650 code details at a glance

The table below summarizes the reference data for HCPCS Code J8650 as it stood in the CMS HCPCS Level II annual update files.

What nabilone (Cesamet) is used for

Nabilone is a synthetic cannabinoid that mimics the action of delta-9-tetrahydrocannabinol (THC) without being derived from the cannabis plant. The FDA approved it as Cesamet for chemotherapy-induced nausea and vomiting (CINV) in patients who did not respond to conventional antiemetics. That narrow indication shapes how you link diagnosis codes on the claim.

Nabilone is also a Schedule II controlled substance under the Controlled Substances Act. Prescribing and dispensing records have to stand up to a clinical audit and a billing audit alike. The schedule drives payer behavior too, since many commercial plans want clinical justification before they approve a Schedule II antiemetic.

Assembling that justification before the claim goes out is cheaper than appealing afterward. It heads off the denials that arrive on medical necessity or compliance grounds.

• Drug name: Nabilone
• Brand name: Cesamet
• Drug class: Synthetic cannabinoid antiemetic
• DEA schedule: Schedule II (verify current status against DEA scheduling data)
• FDA-approved indication: Chemotherapy-induced nausea and vomiting (CINV)
• Clinical use context: Prescribed when standard antiemetics have failed

Is J8650 still valid? Code status and the 2026 deletion

No, J8650 is not a valid billable HCPCS code as of January 2026. CMS deleted it in the January 2026 annual update. Medicare Administrative Contractors (MACs) including Noridian and CGS confirmed it in their 2026 HCPCS bulletins. Any claim submitted with J8650 after the effective date is rejected by Medicare and by commercial payers whose edits follow the CMS HCPCS master file.

HCPCS deletions happen for a few reasons. The drug may have been assigned a newer and more specific code, the product may have been discontinued, or CMS may have restructured the range. For J8650, the CMS HCPCS annual update crosswalk file carries the deletion rationale and the authoritative replacement designation.

MAC bulletins are the practical first stop. Noridian, CGS, and the other regional contractors summarize deleted codes and their crosswalks in plain language, usually ahead of the effective date.

Replacement code: what to bill instead of J8650

No named replacement code for nabilone is confirmed in the CMS January 2026 materials published so far. Until one is, work from the crosswalk file rather than from a code someone posted in a forum. Five steps settle it.

1. Download the CMS January 2026 HCPCS update file from the CMS list of CPT/HCPCS codes and search for J8650. The crosswalk column shows the replacement code where one has been assigned.
2. Check your MAC’s 2026 HCPCS update bulletin. Noridian and CGS both published January 2026 update guides. Search the deleted-code section for J8650 or for nabilone.
3. Consult a HCPCS code lookup. The deleted code entry in AAPC Codify often notes the crosswalk in its code details panel.
4. If no replacement code exists, practices typically bill nabilone with a Not Otherwise Classified code such as J8999, prescription drug, oral, not otherwise specified. Pair it with strong documentation and verify the pathway with your MAC first.
5. Update the charge master and the EHR billing tables as soon as the replacement is confirmed. Every day a deleted code stays active is another day of denials to rework.

Medicare coverage and reimbursement for nabilone

Medicare coverage for nabilone splits between Part D and Part B, and the split decides where the claim is routed. Most oral prescription drugs, nabilone included, sit under Part D, the pharmacy benefit.

Part B can apply through the oral antiemetic drug replacement provision at SSA section 1861(s)(2)(T). That provision governs oral antiemetics rather than oral anticancer agents, which is the distinction that trips practices up. CMS applies it through LCD L33827. The LCD sets out when an oral antiemetic used in place of an intravenous one is covered alongside a chemotherapy regimen.

Whether a given nabilone order qualifies depends on that LCD and on the patient’s regimen. Do not route a nabilone claim to Part B without reading it first.

For practices that billed nabilone under Part B with J8650, the deletion raises two questions at once. Which code replaces it, and does the replacement carry the same coverage pathway?

Fee schedule amounts change every year, so quote the current allowable rather than a figure from a previous cycle. The CMS Physician Fee Schedule lookup tool returns the rate for the applicable code, adjusted for your locality.

How to bill oral antiemetic drugs under HCPCS

Billing an oral antiemetic under HCPCS Level II starts with matching the code to the drug and its dosage unit. The next step is linking the diagnosis codes that establish medical necessity. The J8500-J8999 range exists for that job and sits apart from the injectable J-codes. The diagram below shows the two decisions a nabilone charge has to clear before it reaches a payer.

The checklist below applies to nabilone’s replacement code and to the other agents in the same range.

1. Confirm the HCPCS code is active. Check it against the current CMS HCPCS master file before submission. A deleted code denies on the first pass, every time.
2. Calculate units correctly. For J8xxx codes the unit is typically 1 mg, so report units equal to the total milligrams. Under-reporting or over-reporting units triggers a dosage mismatch denial.
3. Link the ICD-10-CM diagnosis codes in the right order. Sequence the nature of the effect first, such as R11.2 for nausea with vomiting, then report the adverse-effect code T45.1X5A as a secondary diagnosis. Payers cross-check drug HCPCS codes against the diagnoses on the claim.
4. Check prior authorization requirements. Commercial payers and some Medicare Advantage plans require authorization for Schedule II antiemetics. A claim without a valid authorization number denies even when the code is right.
5. Document the prescribing provider’s credentials. Controlled substance prescribing records must be in the patient chart and available for audit.
6. Submit on the CMS-1500 or the 837P equivalent. Oral drug HCPCS codes go on the professional claim in most outpatient oncology settings, not the UB-04.

Charge entry is where most of this is won or lost. A clean claim checklist covers the fields that have to be complete before submission. Oral drug charges usually fail on units, on diagnosis sequence, or on a missing authorization number.

Private payer and Medicaid coverage considerations

Commercial and Medicaid coverage for nabilone varies more than Medicare does, so treat each payer as its own policy review. A few patterns hold across most plans.

• Prior authorization is common. Most commercial plans require it for nabilone, given the Schedule II status and the cost. A missing authorization number is the most frequent denial reason in this drug class.
• Step therapy requirements apply. Payers often want documentation that first-line antiemetics failed, including 5-HT3 antagonists and NK1 antagonists.
• Medicaid coverage varies by state. Some state programs cover nabilone under the pharmacy benefit, while others restrict it or route it through a specialty pharmacy. Check the state preferred drug list before billing.
• Medicare Advantage formularies differ. A drug covered under traditional Part D is not automatically covered by every MA plan, and the authorization rules differ too.

Verifying the patient’s drug benefit before the visit costs less than working the denial afterward. For an oncology-adjacent drug, check the specific drug tier rather than stopping at active or inactive coverage.

Common billing errors and claim denials

Five errors account for most denials on an oral antiemetic charge, and each one has a specific fix at charge entry.

A structured denial workflow recovers deleted-code denials faster, because the reason code, the corrected code, and the resubmission all sit in one queue. Without one, these claims age past the timely filing window and turn into write-offs.

Grouping denials by reason code from the remittance advice is what turns a payer file into a work list. It also makes a pattern obvious, such as a whole cohort of J8650 claims denying after January 2026. Knowing the denial codes to watch shortens the time between the rejection and the corrected claim.

How Pabau supports HCPCS billing for oral chemotherapy drugs

Practices billing oral chemotherapy and antiemetic drugs carry an annual risk. The J8xxx codes change each January, and a single missed deletion can produce a month of denied claims before anyone notices the pattern.

Pabau’s accurate claims management software structures charge entry, holds claims for review before they go out, and tracks denials by reason code. Billing staff see the HCPCS code, the unit count, and the linked diagnoses on one screen while the claim is still editable.

Authorization paperwork can sit on the patient’s record rather than in a separate folder, so the number is on hand when the claim is built. Denials that do land are grouped by reason code, which makes a wave of post-update rejections visible within days instead of at month end.

Keep HCPCS code changes out of your denial queue

Pabau structures charge entry and reviews claims before they go out. It also tracks denials by reason code, so an annual HCPCS update does not cost you a month of rework. See how it works for oral drug billing.

Book a demo

Conclusion

J8650 is gone, and the cost of ignoring that shows up as denied claims rather than as a coding technicality. Pull the CMS January 2026 crosswalk, correct the charge master, then work the open receivable for J8650 claims still inside the filing window.

The judgment worth keeping is that a deleted drug code is rarely only a code change. Nabilone’s deletion reopens the Part B question as well, and the answer sits in LCD L33827 rather than in your charge master. Book a demo to see how Pabau keeps an annual HCPCS update from turning into a month of denials.

Continue your research

Need guidance on billing compliance for specialty drugs? Medical billing compliance covers the regulatory framework practices follow when billing controlled substances.

Want to reduce your first-pass denial rate on drug claims? Denial management in healthcare walks through a workflow for identifying, appealing, and preventing HCPCS denials.

Looking for a primer on how revenue cycle workflows connect to HCPCS billing? Revenue cycle management explained covers the process from charge capture through payment posting.

Frequently asked questions